TMPRSS2阻害剤は,パン-SARS-CoV-2の予防と治療として作用する
Tirosh Shapira1, I Abrrey Monreal2, Sébastien P Dion3
1Department of Microbiology and Immunology, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada.
Nature
|March 28, 2022
まとめ
新しい化合物であるN-0385は,II型トランスメブランセリンタンパク質酶 (TTSP) を標的として,SARS-CoV-2感染を効果的に抑制する. この小さな分子は,COVID-19とその新たな変種に対する早期治療の選択肢として有望であることが示されています.
科学分野:
- ウイルス学
- 薬理学について
- 感染症
背景:
- SARS-CoV-2によって引き起こされるCOVID-19は,依然として世界的な健康危機です.
- ワクチンの有効性は,新興のSARS-CoV-2変種によって挑戦されています.
- ホスト指向の治療は,変異性耐性との闘いの戦略を提供します.
研究 の 目的:
- SARS-CoV-2 侵入の小分子阻害剤を特定し,特徴づけること.
- COVID-19 治療のためのII型トランスメブランセリンプロテアゼ (TTSP) を標的とする可能性を評価する.
- SARS-CoV-2とその変種に対するN-0385の有効性を評価する.
主な方法:
- SARS-CoV-2 感染症の阻害剤に対する小分子スクリーニング.
- ヒトの肺細胞 (Calu-3) とコロノイドを用いた試験.
- COVID-19のK18-ヒトACE2トランスジェニックマウスモデルを用いた体内研究.
- SARS-CoV-2変種 (アルファ,ベータ,ガンマ,デルタ) に対するN-0385の抑制作用の評価.
主要な成果:
- N-0385は,SARS-CoV-2を阻害する低ナノモラーの効能と高い選択性 (選択性指数> 10^6) を示した.
- この化合物は,細胞培養で懸念される複数のSARS-CoV-2の侵入を効果的に抑制しました.
- N-0385は,重度のCOVID-19のマウスモデルにおいて,単発投与後でも重要な予防効果と治療効果を提供しました.
結論:
- TTSP媒介のスパイクタンパク質の成熟は,体内でのSARS-CoV-2感染において極めて重要です.
- N-0385は,SARS-CoV-2の侵入とウイルス感染の強力な阻害剤です.
- N-0385は,COVID-19および新たな変種に対する有望な早期治療法です.
関連する概念動画
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
265
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
265
Eukaryotic Transcription Inhibitors
10.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
664
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
664
Subviral Agents
151
Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
151


